Case-Based Roundtable Meetings Spotlight: February 2, 2022

Hanna Discusses Efficacy Results of Different Treatments in RET-Positive Lung Cancer

February 19, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Nasser H. Hanna, MD, discussed the results of the LIBRETTO-001, ARROW, and other trials of patients with lung cancer with RET mutations or other biomarkers.

Roundtable Discussion: Targeted Therapies for Relapsed/Refractory Multiple Myeloma

February 18, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Kenneth Shain, MD, PhD, discussed the case of a patient whose multiple myeloma progressed 1 year after treatment with daratumumab, bortezomib, and dexamethasone.

Awan Compares BTK Inhibition and Other Treatments for a Patient With CLL

February 18, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.

Munoz Covers Multiple Regimens for the Treatment of DLBCL

February 15, 2022

Clinical Articles

During a Targeted Oncology live virtual event, Javier L. Munoz, MD, MBA, discussed third-line treatments for DLBCL including chimeric antigen receptor T-cell therapy and targeted treatments.